ClinicalTrials.gg
RecruitingNCT07192614ACTIVATED-4-PCUpdated Sep 2, 2026

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

A Phase 1/2 interventional study of AZD6621 in Prostate Cancer, sponsored by AstraZeneca. Recruiting at 26 sites in 9 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Prostatic Neoplasms by AstraZeneca — 15 open to participants now, 29 under way, 8 of them phase 3. Prostatic Neoplasms · AstraZeneca.

Planned enrollment
41st of 60
52 · median 110
Started
2025
with 9 others
Phase 1/2
11 of 91
6 open now
Primary completion
2029-03
later than 20 of 28 live
Registered
82nd of 91
by date

Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 41st largest by planned enrollment of the 60 interventional ones that give a count, is one of 10 that started in 2025, is one of 11 in phase 1/2, reaches primary completion later than 20 of the 28 other live ones, and was the 82nd registered.

Prostatic Neoplasms

7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 91 studies in Prostatic Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Prostatic Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621. The study is split into different modules which will look at AZD6621 delivered by different methods. The study is also further split into 2 parts, Part A which will test different dose levels of AZD6621 to determine which doses are the best in terms of safety and side effects (dose escalation), and Part B will further test at least two AZD6621 doses in a larger group of participants (dose expansion).

Read the detailed description

This is a first in human, modular, Phase I/II, open-label, multicenter study of AZD6621, in adult participants with metastatic prostate cancer. The study will consist of study modules, each evaluating safety, tolerability, PK, pharmacodynamics, and anti-tumor activity of AZD6621 in metastatic prostate cancer. The study will also characterize the PK and immunogenicity of AZD6621.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Metastatic Prostate Cancer
  • Prostate Cancer
  • Prostate Adenocarcinoma
  • T Cell-engaging Antibody
  • STEAP2
  • CD3
  • CD8
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of giving signed and complying to the study protocol.
  2. Provision of signed and dated written Optional Genomics Initiative Research Information and Consent Form.
  3. ≥ 18 years of age at the time of signing the informed consent form.
  4. Participants with:

    1. confirmed diagnosis of adenocarcinoma of the prostate
    2. Surgically or medically castrated, with serum testosterone levels ≤ 50 ng/dL (≤ 1.75 nmol/L) ≤ 28 days before first dose of study intervention. Participants without prior surgical castration must be currently taking and willing to continue LHRH agonist or antagonist therapy throughout the duration of the study intervention.
    3. Castration-resistant prostate cancer as defined by disease progression despite castration by orchiectomy or ongoing ADT.
    4. PSA at screening visit ≥ 1 ng/mL.
  5. Provision of baseline fresh or archival tumor of prostate carcinoma is mandatory.
  6. Evidence of disease progression within 6 months prior to screening with at least one of the following:

    1. PSA progression defined by a minimum of 3 rising PSA levels with an interval of ≥ 1 week between each determination.
    2. Radiographic progression of soft tissue disease by v1.1 criteria with or without PSA progression.
    3. Radiographic progression of bone metastasis by PCWG3 criteria with 2 or more documented new bone lesions on a bone scan with or without PSA progression.
  7. Part A: Module 1 and Module 2:

    1. Part A: Module 1 and Module 2 prior anti-cancer treatment requirements as stated in study protocol
    2. Pharmacodynamic backfill cohort(s) only: lesion amenable for biopsy and be willing to undergo biopsy, distinct from any target lesion used in the RECIST v1.1 evaluation, unless there are no other lesions available for biopsy.
  8. Part B: Module 1 and Module 2:

    1. Part B: Module 1 and Module 2 prior anti-cancer treatment requirements as stated in study protocol.
    2. Participants may have received PARP inhibitors or per local treatment guidelines.
    3. Sampling Requirements as stated in study protocol.
  9. PS score of 0 or 1.
  10. Minimum of > 12 weeks.
  11. Adequate hematological, renal, bone marrow, and liver function as documented in the protocol.
  12. Body weight ≥ 35 kg.
  13. Male, as assigned at birth, inclusive of all gender identities.
  14. use by participants or participant partners as documented in the protocol and consistent with local regulations.

Exclusion criteria

Exclusion Criteria

  1. Any evidence of diseases (such as severe or uncontrolled systemic diseases) which in the Investigator's opinion makes it undesirable for the participant to participate in the study.
  2. One or more of the following:

    1. Mean resting interval > 470 ms,
    2. History of QT prolongation associated with other medications that required discontinuation of that medication, or any current concomitant medication known to prolong the QT interval and cause Torsades de Pointes.
    3. Congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first degree relatives.
    4. Inadequate cardiac function of \< 50% on screening cardiac MUGA or ECHO.
  3. Cardiac arrhythmias (such as multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which are symptomatic or require treatment unless controlled by pacemaker; symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia.
  4. History of another primary except for malignancy treated with curative intent with no known active disease (≥ 2 years) before the first dose of study intervention and of low potential risk for recurrence.
  5. History of, or planned organ or stem cell transplantation.
  6. Unresolved toxicity from prior anti-cancer therapy of Grade ≥ 2 (exceptions listed in protocol).
  7. History of Grade ≥ 3 CRS or Grade ≥ 2 ICANS based on ASTCT criteria with prior therapy. CRS must be resolved prior to screening.
  8. Previous history of hemophagocytic lymphohistiocytosis/ macrophage activation syndrome.
  9. Active or prior documented or inflammatory disorders (examples in protocol) within the past 3 years prior to the start of treatment or requiring permanent therapy.
  10. Spinal cord compression unless asymptomatic and treated and stable and not requiring continuous at a dose of > 10 mg prednisone/day or equivalent.
  11. CNS pathology (examples in protocol).
  12. Active or uncontrolled or C virus infection (exceptions listed in the protocol).
  13. Known infection that is not well controlled (definition for HIV infection that is well controlled is listed in protocol).
  14. Radiation therapy within 4 weeks of first dose of study intervention (or local or focal radiotherapy within 2 weeks of first dose).
  15. Prior anti-cancer drug exposure requirement as stated in study protocol
  16. Previous anti-cancer treatment requirements as stated in study protocol
  17. Systemic corticosteroids at doses exceeding 10 mg/day of prednisone or equivalent \< 7 days prior to first dose.
  18. Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose.
  19. Receipt of the last dose of anti-cancer therapy or participation in another clinical study with last dose administered in the last 21 days or 5 half-lives, whichever is shorter

    - CAR-T cell therapy within the last 6 months prior to enrolment on this study.

  20. Participants with a known to AZD6621 or any of its .
  21. Involvement in the planning and/or conduct of the study.
  22. Participant is unlikely to comply with study procedures, restrictions, and requirements (as judged by the Investigator).
  23. Receipt of within 30 days prior to the first dose of study intervention or receipt of COVID-19 vaccination within 72 hours prior to the first dose of study intervention.
  24. Previous enrolment in the present study.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Module 1 - Part A (Dose Escalation)

    AZD6621 Monotherapy - Administration route 1

    Drug: AZD6621

  • Experimental
    Module 2 - Part A (Dose Escalation)

    AZD6621 Monotherapy - Administration route 2

    Drug: AZD6621

  • Experimental
    Module 1/2 - Part B1 (Dose Expansion)

    AZD6621 Monotherapy - Administration route 1 (Module 1) or administration route 2 (Module 2) at Recommended Dose for Expansion 1 (RDE1)

    Drug: AZD6621

  • Experimental
    Module 1/2 - Part B2 (Dose Expansion)

    AZD6621 Monotherapy - Administration route 1 (Module 1) or administration route 2 (Module 2) at Recommended Dose for Expansion 2 (RDE2)

    Drug: AZD6621

Interventions

  • DrugAZD6621

    A T Cell-engaging Antibody that targets STEAP2, CD3, and CD8

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AE), adverse events of special interest (AESI), and serious adverse events (SAE)

    • Number of participants with AEs, AESIs, SAEs, including AEs leading to discontinuation of study intervention and clinically significant alterations from baseline in laboratory parameters, vital signs, ECGs and physical examination results

    Time frame: From time of Informed Consent to 90 days post last dose of study intervention (up to 3 years)

  2. Number of participants with dose-limiting toxicity (DLT), as defined in the protocol (Part A only)

    • A DLT is a toxicity defined by the study protocol that occurs from the first dose of study intervention up to the end of the DLT evaluation period that is assessed as clearly unrelated to the primary disease or intercurrent illness.

    Time frame: From first study dose to 21 to 28 days post first dose

  3. Preliminary anti-tumour activity of AZD6621 (PSA Response Rate) (Part B only)

    • Number of participants with a PSA response rate

    Time frame: Up to 3 years

Secondary outcomes

  1. Preliminary anti-tumour activity of AZD6621 (PSA Response rate) (Part A only)

    • Number of participants with a PSA response rate

    Time frame: Up to 3 years

  2. Preliminary anti-tumour activity of AZD6621 (time to PSA response)

    • Time taken to achieve a PSA response

    Time frame: Up to 3 years

  3. Preliminary anti-tumour activity of AZD6621 (duration of PSA response)

    • Time PSA response lasts

    Time frame: Up to 3 years

  4. Preliminary anti-tumour activity of AZD6621 (durable PSA response rate)

    • Percentage of participants who have a confirmed PSA response with a duration of at least 6 months

    Time frame: Up to 3 years

  5. Preliminary anti-tumour activity of AZD6621 (time to PSA progression)

    • Time taken to achieve PSA progression

    Time frame: Up to 3 years

  6. Preliminary anti-tumour activity of AZD6621 (Radiological Response - RECIST)

    • Radiological response: according to RECIST v1.1 (soft tissue) and PCWG3 (bone)

    Time frame: Up to 3 years

  7. Preliminary anti-tumour activity of AZD6621 (Radiological Response - Target Lesion Percentage change)

    • Percentage change in Target Lesion size according to RECIST v1.1.

    Time frame: Up to 3 years

  8. Preliminary anti-tumour activity of AZD6621 (Overall Survival 12 months)

    • Overall Survival at 12 months

    Time frame: 12 months

  9. Preliminary anti-tumour activity of AZD6621 (Overall Survival)

    • Median Overall Survival

    Time frame: Up to 3 years

  10. Preliminary anti-tumour activity of AZD6621 (SSRE)

    • Time to first symptomatic skeletal-related events (SSRE)

    Time frame: Up to 3 years

  11. Pharmacokinetics of AZD6621 (Serum concentrations)

    • Serum concentrations of the study drug.

    Time frame: From first dose of study intervention to 28 days post last dose of study intervention

  12. Pharmacokinetics of AZD6621 (Cmax)

    • Maximum observed plasma concentration of the study drug (Cmax).

    Time frame: From first dose of study intervention to 28 days post last dose of study intervention

  13. Pharmacokinetics of AZD6621 (AUC)

    • Area under the plasma concentration-time curve (AUC).

    Time frame: From first dose of study intervention to 28 days post last dose of study intervention

  14. Pharmacokinetics of AZD6621 (Tmax)

    • The time it takes for study drug to reach the maximum concentration (Tmax).

    Time frame: From first dose of study intervention to 28 days post last dose of study intervention

  15. Pharmacokinetics of AZD6621 (t1/2)

    • Terminal elimination half life of study drug (t1/2)

    Time frame: From first dose of study intervention to 28 days post last dose of study intervention

  16. Immunogenicity of AZD6621

    • The number and percentage of participants who develop detectable anti-drug antibodies (ADA).

    Time frame: From first dose of study intervention to 28 days post last dose of study intervention

  17. Tumour STEAP2 expression

    • STEAP2 expression in tumour as measured by immunohistochemistry (IHC)

    Time frame: Up to 3 years

07

Study locations

15 of 26 sites recruiting
  • Research Site
    Orlando, Florida 32806, United States
    Recruiting
  • Research Site
    Tampa, Florida 33612, United States
    Recruiting
  • Research Site
    Boston, Massachusetts 02114, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Grand Rapids, Michigan 49546, United States
    Recruiting
  • Research Site
    Commack, New York 11725, United States
    Recruiting
  • Research Site
    Providence, Rhode Island 02903, United States
    Recruiting
  • Research Site
    Brussels, 1200, Belgium
    Not yet recruiting
  • Research Site
    Ghent, 9000, Belgium
    Not yet recruiting
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
    Not yet recruiting
  • Research Site
    Québec, G1J 1Z4, Canada
    Recruiting
  • Research Site
    Beijing, 100142, China
    Recruiting
  • Research Site
    Chengdu, 610041, China
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Guangzhou, 510060, China
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Nanjing, 2100008, China
    Not yet recruiting
  • Research Site
    Chūōku, 104-0045, Japan
    Recruiting
  • Research Site
    Hirakata-shi, 573-1191, Japan
    Recruiting
  • Research Site
    Kashiwa, 277-8577, Japan
    Recruiting
  • Research Site
    Amsterdam, 1066CX, Netherlands
    Not yet recruiting
  • Research Site
    Maastricht, 6229 HX, Netherlands
    Not yet recruiting
  • Research Site
    Seoul, 03080, South Korea
    Recruiting
  • Research Site
    Seoul, 5505, South Korea
    Recruiting
  • Research Site
    Barcelona, 8035, Spain
    Not yet recruiting
  • Research Site
    L'Hospitalet de Llobregat, 08908, Spain
    Not yet recruiting
  • Research Site
    Madrid, 28041, Spain
    Recruiting
  • Research Site
    Cambridge, CB2 0QQ, United Kingdom
    Recruiting
  • Research Site
    Manchester, M20 4BX, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Mar 2029, 41 months after the start.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 41 months is below that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2025
First posted
Sep 25, 2025
StartActual
Sep 30, 2025
Primary completionEst.
Mar 29, 2029
CompletionEst.
Mar 29, 2029
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07192614
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 25, 2025
Start date
Sep 30, 2025
Primary completion
Mar 29, 2029 (estimated)
Completion
Mar 29, 2029 (estimated)
Last update
Sep 2, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion